← Back to signals
PLRX
PLIANT THERAPEUTICS, INC.
Research: Finviz ↗·Perplexity ↗
No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.
Days to cover (short int.)
11.4d↑+15.0%
as of 2026-09-30
Fund 13D/13G Filings (4)
Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).
| Fund | Form | ∆ Shares | % of Class | Since Filing | Filed | Src |
|---|---|---|---|---|---|---|
| Point72 | SC 13G/A | — | 0.1% | — | 2026-02-17 | ↗ |
| Citadel Advisors | SC 13G | +4K | 5.0% | — | 2026-02-09 | ↗ |
| Citadel Advisors | SC 13G | +46K | 4.9% | — | 2026-01-30 | ↗ |
| Citadel Advisors | SC 13G | NEW | 4.9% | — | 2026-01-22 | ↗ |
Tracked Funds Holding (1)
| Fund | Manager | Shares Held | Position Value |
|---|---|---|---|
| Point72 | Steve Cohen | 20K | $0M |
Quarter-end 13F positions for the tracked funds holding this stock.